// App-Quantinova.ai

6615 : Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.

Researchers

Presenter

  • Pedro Nazareth Aguiar

Principal Investigators

  • Pui San Tan

  • Sarah Simko

  • CARMELIA MARIA NOIA BARRETO

  • Barbara Gutierres Aguiar

  • Auro Del Giglio

  • Gilberto Lopes

Medical Centers

  • Faculdade de Medicina do ABC, Santo Andre, Brazil

  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom

  • University of Miami Miller School of Medicine, Miami, FL

  • Instituto Avancos em Medicina, Sao Paulo, Brazil

  • Paulista University, Sao Paulo, Brazil

  • Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

Locations

  • Brazil

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved